Latest Breaking News On - Biochemically recurrent prostate - Page 1 : vimarsana.com

APCCC 2024: PSMA Radioligand Therapy – State of the Art

APCCC 2024: PSMA Radioligand Therapy – State of the Art
urotoday.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from urotoday.com Daily Mail and Mail on Sunday newspapers.

Ken herrmannUniversity of torontoDepartment of nuclear medicineUniversity hospital essenSociety of urologic oncologyProstate cancer consensus conferenceBrief pain inventoryEuropean urologyNuclear medicineRashid sayyidUrologic oncologyClinical fellowProstate specific membraneMetastatic castration resistant prostateAnnounce positive topline resultsRadical prostatectomy

Astellas XTANDI™ (Enzalutamide) Granted European Commission Approval for Use in Additional Recurrent Early Prostate Cancer Treatment Setting

/PRNewswire/ Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced the European Commission (EC) has approved a.

United statesComunidad autonoma de catalunaAntonio alcarazAhsan arozullahEuropean unionDrug administrationEuropean association of urologyEuropean commissionDepartment of urologyAmerican society of clinical oncologyUniversity hospital clinic of barcelonaCommittee for medicinal products human useEuropean medicines agencyAstellas pharma incPrnewswire astellas pharma incHead of oncology development

Astellas XTANDItm (Enzalutamide) Granted European Commission Approval for Use in Additional Recurrent Early Prostate Cancer Treatment Setting

Astellas XTANDItm (Enzalutamide) Granted European Commission Approval for Use in Additional Recurrent Early Prostate Cancer Treatment Setting
lelezard.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lelezard.com Daily Mail and Mail on Sunday newspapers.

Comunidad autonoma de catalunaUnited statesAhsan arozullahAntonio alcarazAmerican society of clinical oncologyEuropean medicines agencyPrnewswire astellas pharma incEuropean commissionCommittee for medicinal products human useHead of oncology developmentEuropean association of urologyUniversity hospital clinic of barcelonaDepartment of urologyDrug administrationEuropean unionAstellas pharma inc

Astellas XTANDI™ (Enzalutamide) Granted European Commission Approval for Use in Additional Recurrent Early Prostate Cancer Treatment Setting

Astellas XTANDI™ (Enzalutamide) Granted European Commission Approval for Use in Additional Recurrent Early Prostate Cancer Treatment Setting
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Comunidad autonoma de catalunaUnited statesAntonio alcarazAhsan arozullahDrug administrationUniversity hospital clinic of barcelonaEuropean medicines agencyEuropean unionCommittee for medicinal products human useAmerican society of clinical oncologyHead of oncology developmentEuropean association of urologyEuropean commissionDepartment of urologyPrnewswire astellas pharma incAstellas pharma inc

Recruitment target achieved for Phase II SAR-Bombesin prostate cancer trial

Recruitment target achieved for Phase II SAR-Bombesin prostate cancer trial
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesNew south walesGuggerm bombesinAlan taylorAndrei iagaruAmerican cancer societyAmerican cancer instituteClarity pharmaceuticalsTechnology platformCancer statistics centerDrug administrationPrnewswire clarity pharmaceuticalsEmission tomographyLead principal investigatorExecutive chairmanTargeted copper theranostic